| abstract |
Pyrimidine derivatives of the formula (I) are described in which: one of Q1 and Q2 or both of Ql and Q2 are substituted on a ring carbon by a substituent of the formula (Ia) [with the proviso that when this present in Q, the substituent of the formula (Ia) is not adjacent to the -NH-1 bond; wherein Ql, Q2, G, Rl, X, Yl, Y2, Z, n and m are as described within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof. Processes for its manufacture, pharmaceutical compositions and its use as cyclin-dependent serine / threonine kinase (CDK) and focal adhesion kinase inhibitors (FAK) are also described. |